Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411191 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDATMKMT2A | |
| Hydrochloric Acid SCHEMBL16038223 | 0.98 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDATMKMT2A | |
| SCHEMBL15154745 | 0.93 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDATMKMT2A | |
| SCHEMBL15475592 | 0.93 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDATMKMT2A | |
| SCHEMBL15154747 | 0.93 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDATMKMT2A | |
| SCHEMBL15174292 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDATMKMT2A | |
| SCHEMBL15171917 | 0.92 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDATMKMT2A | |
| Hydrochloric Acid SCHEMBL16038222 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDATMKMT2A | |
| SCHEMBL15171921 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDATMKMT2A | |
| SCHEMBL15171922 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016182898-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2016-11-17 | — | — | WO | claimed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| EP-1735267-B1 | AMINOALKYL SUBSTITUTED ESTERS AND AMIDES OF FUMARIC ACID FOR NEUTRALISING MALODOR | GIVAUDAN SA (CH) | 2008-07-23 | — | — | EP | claimed |
| US-20070009475-A1 | Aminoalkyl substituted esters and amides of fumaric acid for neutralizing malodor | GIVAUDAN SA (CH) | 2007-01-11 | — | — | US | claimed |
| EP-1735267-A1 | AMINOALKYL SUBSTITUTED ESTERS AND AMIDES OF FUMARIC ACID FOR NEUTRALISING MALODOR | Givaudan SA (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2005021051-A1 | AMINOALKYL SUBSTITUTED ESTERS AND AMIDES OF FUMARIC ACID FOR NEUTRALISING MALODOR | GIVAUDAN SA (CH) | 2005-03-10 | — | — | WO | claimed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-4230264-A2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2023-08-23 | — | — | EP | disclosed |
| EP-3366668-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2023-06-21 | — | — | EP | disclosed |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-06-20 | — | — | US | disclosed |
| CN-115531366-A | Method of treating multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115501218-A | Methods of treating multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-113368092-A | Methods of treating multiple sclerosis | 比奥根玛公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20140051705-A1 | Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use | XENOPORT, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2013119791-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203753-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-1735267-B1 | AMINOALKYL SUBSTITUTED ESTERS AND AMIDES OF FUMARIC ACID FOR NEUTRALISING MALODOR | GIVAUDAN SA (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-20070009475-A1 | Aminoalkyl substituted esters and amides of fumaric acid for neutralizing malodor | GIVAUDAN SA (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1735267-A1 | AMINOALKYL SUBSTITUTED ESTERS AND AMIDES OF FUMARIC ACID FOR NEUTRALISING MALODOR | Givaudan SA (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005021051-A1 | AMINOALKYL SUBSTITUTED ESTERS AND AMIDES OF FUMARIC ACID FOR NEUTRALISING MALODOR | GIVAUDAN SA (CH) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051705-A1 | Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use | FH, APC, HTT | ALDH1A1 2754/4885KDM4E 3249/4885HPGD 1190/4885 |
| US-20130203753-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | FH, APC, HTT | ALDH1A1 2754/4885KDM4E 3249/4885HPGD 1190/4885 |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | ALDH1A1 363/4885KDM4E 1909/4885HPGD 91/4885 |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | ALDH1A1 363/4885KDM4E 1909/4885HPGD 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.